Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
4 Z" R5 g! }5 ?0 ], X- S8 Q. ]7 f* h0 P8 f0 a. L* T
* u, F- w0 }- T, VSub-category:
- c }4 B% s9 Y# UMolecular Targets
' F; b" _7 D/ E! N0 d$ v" R: H& @$ x; t- c! @2 C
) `, N0 |5 D+ ?6 ]/ RCategory:
, \; ^1 X4 |8 D+ J. qTumor Biology
3 i6 {7 V2 Z; q
! n6 j T* q% ]: p3 V
* Z; Y5 Y( d2 {2 TMeeting:5 }3 d* A! Z' T }5 K2 L- Z) j9 L
2011 ASCO Annual Meeting S# h. V @/ I/ i
# F2 Z5 a9 D! T
( |( w' D/ x6 L- U9 S1 SSession Type and Session Title:
- M/ a$ ?3 G$ Y6 A* ^Poster Discussion Session, Tumor Biology 5 W @ ~/ _* |5 o
) H8 B0 T* _8 F$ U' B8 |$ n- x/ }9 O0 H/ I, a; z
Abstract No:6 I9 z+ @/ W, B& E* [
10517 ! Q- V9 y: c9 l7 ~- ?( m
2 P& W. v: }3 E3 J5 v% S+ f
: @" {* _9 G4 L' n& u" o' C7 X2 ?Citation:
4 J5 Y# n" ]% t V u4 z3 mJ Clin Oncol 29: 2011 (suppl; abstr 10517)
# ^7 O2 Y7 w% y- H$ U: P4 P7 J; L, j* u' M3 _! N3 a
) q, K* Z g7 H2 i9 w) v. ~3 GAuthor(s):) s3 w0 T ^9 K2 K7 S$ C) n( k
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China T4 O+ h I" P8 U3 @( x2 X' P1 r
1 X# g$ b# P( o
' r/ P5 i* g+ J* K
' D, o7 ]0 f/ C% K& L- n+ J- `+ Y: IAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
% v; ]* {, Q9 T# m% J( {
' d* M/ m1 c& DAbstract Disclosures
( M( F# ~, n' b4 m* o! T! ^) Y6 [- ]2 N" P9 }
Abstract:% v* [( X2 K( e2 F4 E# _: p/ U) ~
. ^1 I4 O, p! r1 C o0 k( d/ Z! m8 l, M, _8 D& e/ r
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
; O% C5 I2 [) d+ b: }4 u- K2 x5 Q9 p2 ~3 }1 Z# A$ [
7 u) H1 b4 F' R5 o3 s6 }1 D% q |
四期伴骨转移，没有靶向药，希望多交
父亲于9月份查出肺部问题，一直非常焦虑、迷茫，对这个病的害怕、对治疗方案的不
MET变异肺癌患者必备宝典：20余位专
间质上皮细胞转化因子（MET）基因的异常，是非小细胞肺癌（NSCLC）发展、转移和耐药的
莫树锦教授：ADC药物的“精确爆破手
整理者：雨过天晴审核人：莫树锦教授、包大包、鹰版11月是一年一度的“全球肺癌关注月
董晓荣教授：局部处理的“战术组合拳
整理者：雨过天晴审核人：董晓荣教授、鹰版11月是一年一度的“全球肺癌关注月”。在这
肺癌5、8、10年的路线展望---奥西伏
前几天和我一姐姐吃饭聊天，唉，吃着吃着又聊到我俩的共同伤心事了，她妈去年也得
2 B/ _0 L+ \7 D2 @0 v+ m
显身卡
